Technical Analysis for MGX - Metagenomi, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Fell Below 20 DMA | Bearish | 7.11% | |
Bollinger Band Squeeze | Range Contraction | 7.11% | |
BB Squeeze + Upper Band Touch | Range Contraction | 7.11% | |
Upper Bollinger Band Touch | Strength | 7.11% | |
20 DMA Support | Bullish | 0.48% |
Alert | Time |
---|---|
Upper Bollinger Band Resistance | about 18 hours ago |
Rose Above Previous Day's High | about 19 hours ago |
Rose Above Upper Bollinger Band | about 19 hours ago |
Up 5% | about 19 hours ago |
Up 1 ATR | about 19 hours ago |
Get this analysis on your stocks daily!
- Earnings date: Unknown
Metagenomi, Inc. Description
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Molecular Biology Genetic Engineering CRISPR Genome Editing Biological Engineering Gene Editing Human Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 12.74 |
52 Week Low | 1.85 |
Average Volume | 234,763 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 2.35 |
20-Day Moving Average | 1.98 |
10-Day Moving Average | 1.98 |
Average True Range | 0.15 |
RSI (14) | 50.25 |
ADX | 25.14 |
+DI | 17.30 |
-DI | 14.60 |
Chandelier Exit (Long, 3 ATRs) | 1.72 |
Chandelier Exit (Short, 3 ATRs) | 2.29 |
Upper Bollinger Bands | 2.08 |
Lower Bollinger Band | 1.87 |
Percent B (%b) | 1.12 |
BandWidth | 10.93 |
MACD Line | -0.09 |
MACD Signal Line | -0.14 |
MACD Histogram | 0.0495 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.38 | ||||
Resistance 3 (R3) | 2.37 | 2.26 | 2.34 | ||
Resistance 2 (R2) | 2.26 | 2.19 | 2.27 | 2.32 | |
Resistance 1 (R1) | 2.19 | 2.15 | 2.23 | 2.20 | 2.31 |
Pivot Point | 2.08 | 2.08 | 2.10 | 2.09 | 2.08 |
Support 1 (S1) | 2.01 | 2.01 | 2.04 | 2.02 | 1.91 |
Support 2 (S2) | 1.90 | 1.97 | 1.91 | 1.90 | |
Support 3 (S3) | 1.83 | 1.90 | 1.88 | ||
Support 4 (S4) | 1.84 |